James R. Berenson

Dr. James R. Berenson is the Founder of the Institute for Myeloma & Bone Cancer Research (IMBCR) and serves as its Medical and Scientific Director since 2003.   IMBCR is a mission-driven 501(c)3 non-profit institute and is committed to advance the monitoring and treatment of multiple myeloma (MM) patients by connecting possibility through scientific innovation leading to personalized and continuous optimized patient care. 

In addition, he is President and Medical Director of Berenson Cancer Center.  This is a clinic that specializes in the care of patients with multiple myeloma and related diseases. 

Dr. Berenson is also President and CEO of ONCOtherapeutics, a CRO that conducts clinical trials in oncology which are mostly related to multiple myeloma. 

Also, he is the Founder and President of ONCOtracker.  This company is a private biotech focused on myeloma-related products.  

Dr. Berenson has authored nearly 300 peer-reviewed publications and contributed to multiple book chapters. He has served as a member of the National Institutes of Health – Center for Scientific Review, Clinical Oncology Study Section and is a member of the Scientific Boards of the Multiple Myeloma Research Foundation and the International Myeloma Foundation. Dr. Berenson has also served on both the Foundation and the Scientific Boards of the Leukemia, Lymphoma and Myeloma Society. Additionally, Dr Berenson is Section Editor for Supportive Cancer Therapy and on the Editorial Boards of: Annals of Hematology, Annals of Oncology, British Journal of Hematology, Clinical Advances in Hematology & Oncology, Clinical Cancer Research, Clinical Lymphoma & Myeloma, Critical Reviews in Oncogenesis, Targeted Oncology, and Current Opinion in Supportive and Palliative Care.